Glomerular permselectivity in early stages of overt diabetic nephropathy

被引:0
|
作者
Andersen, S
Blouch, K
Bialek, J
Deckert, M
Parving, HH
Myers, BD
机构
[1] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Stanford, CA 94305 USA
[2] Steno Diabet Ctr, Copenhagen, Denmark
关键词
filtration barrier defect; nephropathic diabetes; proteinuria; ficol; albuminuria; immunoglobulinuria;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Impairment of glomerular size selectivity has been demonstrated by the dextran-sieving technique in nephropathic diabetics with heavy, but not mild proteinuria. The purpose of the present study was to determine whether such a barrier defect could be demonstrated with mild proteinuria by substituting Ficoll 70, a polysucrose, for dextran as a probe of the filtration barrier. Methods. Differential solute clearances were performed in 12 individuals with early diabetic nephropathy on two occasions: after 60 days of treatment with losartan 50 mg daily or a placebo. An uncharged preparation of nonreabsorbable Ficoll 70 was infused along with inulin. Fractional clearance (theta) of Ficoll of discrete size was determined after separating molecules in urine and plasma in narrow 2 Angstrom fractions over a 20 to 60 Angstrom radius interval by size exclusion high-performance liquid chromatography (HPLC). A hydrodynamic theory of hindered ficoll transport through water-filled pores was used to characterize the pore size distribution of the glomerular barrier. Results. The theta for Ficoll molecules with radii >50 Angstrom was selectively enhanced in placebo-treated diabetic nephropathy versus corresponding theta in healthy control subjects (N = 12). Computations revealed a lower distribution of glomerular pores that was unaltered in nephropathic diabetics. However, an upper distribution of large, shunt-like pores was more prominent, exceeding healthy controls by one order of magnitude in diabetic nephropathy (P = 0.01). A trend to lower theta for Ficoll in the 56 to 60 Angstrom radius range during losartan therapy is computed to have lowered the fraction of shunted filtrate by 26 to 44%, depending on whether glomerular pressure declined. The corresponding reduction in theta for endogenous albumin, IgG, and IgG(4) was by 19 to 23% (P < 0.05). Conclusion. Our findings suggest that shunt-like defects, partially reversible by angiotensin II blockade, are present early in the course of diabetic nephropathy. We estimate that such defects can account for immunoglobulinuria in this disorder. Additional impairment of either charge- or shape-selectivity must be invoked to explain the observed level of albuminuria, however.
引用
收藏
页码:2129 / 2137
页数:9
相关论文
共 50 条
  • [21] Increased expression of heparanase in overt diabetic nephropathy
    van den Hoven, M. J.
    Rops, A. L.
    Bakker, M. A.
    Aten, J.
    Rutjes, N.
    Roestenberg, P.
    Goldschmeding, R.
    Zcharia, E.
    Vlodavsky, I.
    van der Vlag, J.
    Berden, J. H.
    KIDNEY INTERNATIONAL, 2006, 70 (12) : 2100 - 2108
  • [22] Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy
    Nielsen, Stine E.
    Andersen, Steen
    Zdunek, Dietmar
    Hess, Georg
    Parving, Hans-Henrik
    Rossing, Peter
    KIDNEY INTERNATIONAL, 2011, 79 (10) : 1113 - 1118
  • [23] GLOMERULAR BARRIER FUNCTION IN DIABETIC NEPHROPATHY
    MYERS, BD
    WINETZ, JA
    MICHAELS, AS
    KIDNEY INTERNATIONAL, 1982, 21 (01) : 231 - 231
  • [24] Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy
    Satko, SG
    Langefeld, CD
    Daeihagh, P
    Bowden, DW
    Rich, SS
    Freedman, BI
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (03) : 489 - 494
  • [25] Role of manganese superoxide dismutase inactivation in the early stages of diabetic nephropathy
    Munusamy, S
    Brock, RW
    Saba, H
    MacMillan-Crow, LA
    FASEB JOURNAL, 2006, 20 (05): : A1139 - A1139
  • [26] No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy
    van den Born, Jacob
    Pisa, Brenda
    Bakker, Marinka A. H.
    Celie, Johanna W. A. M.
    Straatman, Carin
    Thomas, Steven
    Viberti, Gian C.
    Kjellen, Lena
    Berden, Jo H. M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (40) : 29606 - 29613
  • [27] GLOMERULAR-LESIONS (GL) DURING THE EARLY STAGES OF EXPERIMENTAL REFLUX NEPHROPATHY (RN)
    TORRES, VE
    KRAMER, SA
    HOLLEY, KE
    HARTMAN, GW
    ZOLLMAN, PE
    EUROPEAN JOURNAL OF PEDIATRICS, 1983, 140 (02) : 172 - 172
  • [28] Control of albuminuria in overt diabetic nephropathy: durability counts
    Glassock, Richard J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (09) : 1371 - 1373
  • [29] Pioglitazone mitigates inflammation in patients with overt diabetic nephropathy
    Williams R.
    Nature Clinical Practice Nephrology, 2006, 2 (5): : 237 - 237
  • [30] Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia
    Aso, Y
    Yoshida, N
    Okumura, K
    Wakabayashi, S
    Matsutomo, R
    Takebayashi, K
    Inukai, T
    CLINICA CHIMICA ACTA, 2004, 348 (1-2) : 139 - 145